SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Down 45.4% in September

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a large decrease in short interest in September. As of September 15th, there was short interest totaling 23,700 shares, a decrease of 45.4% from the August 31st total of 43,400 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 60,600 shares, the short-interest ratio is presently 0.4 days. Based on an average daily trading volume, of 60,600 shares, the short-interest ratio is presently 0.4 days. Currently, 0.1% of the company’s shares are sold short.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Saturday, September 27th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $8.00.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Ridgewood Investments LLC increased its position in shares of SOPHiA GENETICS by 1,930.5% during the 1st quarter. Ridgewood Investments LLC now owns 40,610 shares of the company’s stock valued at $135,000 after purchasing an additional 38,610 shares during the last quarter. Silverberg Bernstein Capital Management LLC increased its position in shares of SOPHiA GENETICS by 31.8% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 45,715 shares of the company’s stock valued at $142,000 after purchasing an additional 11,040 shares during the last quarter. Rathbones Group PLC purchased a new stake in shares of SOPHiA GENETICS during the 2nd quarter valued at $504,000. Federated Hermes Inc. increased its position in shares of SOPHiA GENETICS by 89.0% during the 1st quarter. Federated Hermes Inc. now owns 189,000 shares of the company’s stock valued at $627,000 after purchasing an additional 89,000 shares during the last quarter. Finally, Ensign Peak Advisors Inc purchased a new stake in shares of SOPHiA GENETICS during the 2nd quarter valued at $775,000. 31.59% of the stock is owned by hedge funds and other institutional investors.

SOPHiA GENETICS Trading Down 1.6%

NASDAQ SOPH opened at $4.40 on Friday. The firm has a market capitalization of $297.35 million, a P/E ratio of -10.00 and a beta of 1.10. The business has a fifty day simple moving average of $3.48 and a 200 day simple moving average of $3.23. SOPHiA GENETICS has a 12 month low of $2.58 and a 12 month high of $4.92. The company has a current ratio of 3.39, a quick ratio of 3.21 and a debt-to-equity ratio of 0.62.

SOPHiA GENETICS (NASDAQ:SOPH) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.33 EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.58. The business had revenue of $18.32 million during the quarter, compared to analyst estimates of $17.49 million. SOPHiA GENETICS had a negative return on equity of 30.69% and a negative net margin of 40.99%. SOPHiA GENETICS has set its FY 2025 guidance at EPS. On average, analysts predict that SOPHiA GENETICS will post -0.96 EPS for the current fiscal year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.